Research programme: human cytomegalovirus primase inhibitors - TularikAlternative Names: Human cytomegalovirus primase inhibitors research programme - Tularik; T 0902395
Latest Information Update: 09 Dec 2003
At a glance
- Originator Tularik
- Mechanism of Action Cytomegalovirus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 09 Dec 2003 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 29 Jan 2002 Preclinical development for Cytomegalovirus infections in USA (Unknown route)